Stem cell‐derived exosomes in the treatment of melasma and its percutaneous penetration
Lasers in Surgery and Medicine · 2023-02 · 55 (2) · 178-189
DOI: 10.1002/lsm.23628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lasers in Surgery and Medicine, online erschienen am 27.12.2022. Verfasst von Ting Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery and Regenerative Medicine, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Exosomes, Mesenchymal Stem Cells, Melanosis. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell‐derived exosomes (hUCMSC‐Exos) could serve as a novel cell‐free therapeutic strategy in regenerative and esthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. In this study, we aim to explore the safety and efficacy of hUCMSC‐Exos in the treatment of melasma and the means to promote its percutaneous penetration. Materials and Methods In the animal study about the effect of penetration, percutaneous penetration of PKH67‐labeled hUCMSC‐Exos was studied under microneedles, 1565 nm nonablative fractional laser (NAFL), and a plasma named Peninsula Blue Aurora Shumin Master (PBASM) treatments, observed by confocal laser scanning microscopy. In the clinical application study, 60 patients with melasma treated in our department were divided into four groups. NAFL combined with normal saline treatment was used for Group A. Microneedles, NAFL, and PBASM combined with hUCMSC‐Exos treatments were used for Groups B, C, and D, respectively. Each patient received four treatments at 1‐month intervals. Assessments were done using the degree of pain posttreatment, melasma area and severity score, improvement rate, physician global assessment score, satisfaction, and complications. Results In the animal study about the effect of penetration, hUCMSC‐Exos can penetrate the deep dermis under microneedles, NAFL, and PBASM treatments. In the clinical application study, compared with Group A, Groups B, C, and D showed significantly improved therapeutic effect and patient satisfaction ( p < 0.05), and there was no significant difference among Groups B, C, and D.( p > 0.05). Patients in Group B reported higher pain levels than those in the other three groups ( p < 0.05); the treatment experience of patients in Group D was better. Conclusion hUCMSC‐Exos can improve the symptoms of melasma safely and effectively. Compared with microneedles, NAFL and PBASM can also achieve a good effect toward promoting penetration. These findings are worthy of exploration and clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic Surgery and Regenerative Medicine, Fujian Medical University Union Hospital, Fuzhou, China.
ORCID-Profile: Ting Wang
Zitieren
APA
Wang, T., Gao, H., Wang, D., Zhang, C., Hu, K., Zhang, H., Lin, J., & Chen, X. (2023). Stem cell‐derived exosomes in the treatment of melasma and its percutaneous penetration. Lasers in Surgery and Medicine, 55(2), 178-189. https://doi.org/10.1002/lsm.23628
Vancouver
Wang T, Gao H, Wang D, Zhang C, Hu K, Zhang H, et al. Stem cell‐derived exosomes in the treatment of melasma and its percutaneous penetration. Lasers in Surgery and Medicine. 2023;55(2):178-189. doi:10.1002/lsm.23628
BibTeX
@article{Wang2023,
author = {Wang, Ting and Gao, Hangqi and Wang, Dezhi and Zhang, Chaoyu and Hu, Kailun and Zhang, Haoruo and Lin, Jian and Chen, Xiaosong},
title = {Stem cell‐derived exosomes in the treatment of melasma and its percutaneous penetration},
journal = {Lasers in Surgery and Medicine},
year = {2023},
volume = {55},
number = {2},
pages = {178--189},
doi = {10.1002/lsm.23628}
}
EUVIMED